Low Phenylalanine Diet for Mothers With Phenylketonuria (PKU)

NCT ID: NCT00065299

Last Updated: 2005-06-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 572 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1984-05-31
• Study Completion Date: 2000-04-30

Brief Summary

Phenylketonuria (PKU) is a rare genetic condition. If not treated, PKU can cause severe mental retardation. Women with PKU are advised to eat a special diet when pregnant to prevent mental retardation in their children. This study will evaluate the effects of that diet on the children of mothers with PKU.

Detailed Description

PKU is an autosomal recessive trait caused by the absence of phenylalanine hydroxylase. Phenylalanine hydroxylase is an enzyme involved in the metabolism of phenylalanine (Phe). When phenylalanine hydroxylase is absent or defective, Phe levels rise and toxic Phe metabolites accumulate, causing central nervous system injury. PKU is a treatable disease. Affected individuals must adhere to a diet low in Phe during childhood. Women with PKU should also adhere to a low Phe diet before and during pregnancy to avoid fetal damage. The offspring of women with untreated maternal hyperphenylalaninemia (HPA) usually exhibit mental retardation, microcephaly, growth retardation, and other congenital anomalies. This study will examine the effect of a restricted Phe diet on reproductive outcome in women with maternal HPA.

Participants in this study will be women with HPA whose blood Phe values are persistently greater than 4 mg/dl. Those women with blood Phe values consistently greater than 8 mg/dl will be placed on a Phe restricted diet to maintain plasma Phe concentrations between 2 and 8 mg/dl. This level of control is practical and achievable. Due to a gradient of increasing Phe level from mother to fetus, levels in the latter would vary from 3.5 to 12 mg/dl; these levels are usually associated with normal outcomes. Women will be monitored throughout their pregnancy on obstetric, biochemical, and nutritional parameters. Women on the Phe restricted diet will be given enough Phe-limited protein, calories, vitamins, and minerals to maintain adequate nutritional status. Folate supplementation will be provided. If indicated clinically, tyrosine (Tyr) and supplemental trace metals will be prescribed.

A matching control sample of women and their offspring will be developed in collaboration with associated coordinating and collaborating centers. The offspring of both groups of mothers will be followed as long as the project permits. Those offspring born to mothers admitted to the project during the first 2 to 3 years of the study will be assessed on their intellectual ability and physical health, as well as academic achievement in school. Those admitted during the last 3 to 4 years of the study will be assessed on their intellectual ability and physical health, recognizing that limited data will be available for these offspring.

Conditions

Phenylketonuria

Keywords

Hyperphenylalaninemia; PKU; Maternal PKU; Pregnancy outcome; Phenylalanine restricted diet; Tyrosine supplementation; Maternal hyperphenylalanemia during pregnancy

Study Design

• Allocation Method: NON_RANDOMIZED
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Restricted phenylalanine diet

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Live in community setting
• Become pregnant or give birth during the term of the investigation
• Identified early in pregnancy
• Dietary therapy instituted prior to conception whenever possible
• Diagnosis of PKU based on results of Phe challenge, or clear diagnostic evidence in medical record
• Blood Phe > 4 mg/dl
• Intellectually able to understand and comply with the requirements of the Phe restricted diet, understand an informed consent, and adequately communicate with clinic personnel
• IQ > 70

• Heterozygous sisters to HPA women
• Matched control from maternity facility; pregnancy and offspring from a non-PKU female and a PKU male

Exclusion Criteria

• Women with evidence of pterin defect

• Minimum Eligible Age: 0 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

Sponsor Role: lead

Principal Investigators

Richard Koch, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Southern California

Reuben Matalon, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Illinois at Chicago

Bobbye M. Rouse, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Texas at Galveston

Locations

University of Southern California School of Medicine

Los Angeles, California, United States

University of Illinois at Chicago

Chicago, Illinois, United States

University of Texas Medical Branch at Galveston

Galveston, Texas, United States

Countries

United States

References

Levy HL, Guldberg P, Guttler F, Hanley WB, Matalon R, Rouse BM, Trefz F, Azen C, Allred EN, de la Cruz F, Koch R. Congenital heart disease in maternal phenylketonuria: report from the Maternal PKU Collaborative Study. Pediatr Res. 2001 May;49(5):636-42. doi: 10.1203/00006450-200105000-00005.

Reference Type: BACKGROUND

PMID: 11328945 (View on PubMed)

Koch R, Levy HL, Matalon R, Rouse B, Hanley WB, Trefz F, Azen C, Friedman EG, de la Cruz F, Guttler F, et al. The international collaborative study of maternal phenylketonuria: status report 1994. Acta Paediatr Suppl. 1994 Dec;407:111-9. doi: 10.1111/j.1651-2227.1994.tb13468.x.

Reference Type: BACKGROUND

PMID: 7766945 (View on PubMed)

Matalon R, Michals K, Azen C, Friedman E, Koch R, Rouse B, Hanley WB, de la Cruz F. Maternal PKU Collaborative Study: pregnancy outcome and postnatal head growth. J Inherit Metab Dis. 1994;17(3):353-5. doi: 10.1007/BF00711828. No abstract available.

Reference Type: BACKGROUND

PMID: 7807951 (View on PubMed)

Koch R, Levy HL, Matalon R, Rouse B, Hanley W, Azen C. The North American Collaborative Study of Maternal Phenylketonuria. Status report 1993. Am J Dis Child. 1993 Nov;147(11):1224-30. doi: 10.1001/archpedi.1993.02160350098015.

Reference Type: BACKGROUND

PMID: 8237918 (View on PubMed)

Koch R, Hanley W, Levy H, Matalon R, Rouse B, Dela Cruz F, Azen C, Gross Friedman E. A preliminary report of the collaborative study of maternal phenylketonuria in the United States and Canada. J Inherit Metab Dis. 1990;13(4):641-50. doi: 10.1007/BF01799519.

Reference Type: BACKGROUND

PMID: 2122127 (View on PubMed)

Other Identifiers

1N01HD23148

Identifier Type: -

Identifier Source: secondary_id

1N01HD23155

Identifier Type: -

Identifier Source: secondary_id

1N01HD23156

Identifier Type: -

Identifier Source: secondary_id

NICHD-PKU

Identifier Type: -

Identifier Source: org_study_id